Unlocking the Promise of Genome Editing to Deliver Life-Changing Medicines

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.editasmedicine.com

Recent News

February 15, 2017
Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference

February 10, 2017
Editas Medicine to Present at Upcoming February Investor Conferences

January 9, 2017
Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference

Read More News

Associated Team Members

Alexis Borisy